TUCSON, Ariz., August 21, 2025 — Critical Path Institute’s® (C-Path) Huntington’s Disease Regulatory Science Consortium (HD-RSC) is thrilled to welcome its newest member, the Huntington’s Disease Youth Organization (HDYO).
HDYO is a Huntington’s disease (HD) community- focused international nonprofit with the mission of supporting, educating, and empowering younger individuals, up to 35 years old, affected by HD. Their mission covers both people diagnosed with HD, as well as those with family living with HD. HDYO regularly publishes HD related news updates and additionally provides resources for people and families affected by HD. HDYO is also a leader of the HD Community Advisory Board (HD-CAB), a coalition of international HD focused patient advocacy organizations with the mission of injecting HD community perspectives into ongoing HD clinical trials and studies.
HD-RSC provides a neutral forum and collaborative framework to convene diverse experts across the broad HD community to contribute data and generate regulatory grade drug development tools, thus catalyzing efficiency and impact for novel medical product development for HD.
“Bringing HDYO into HD-RSC tangibly demonstrates the fundamental importance of the HD community. By partnering with lived experience advocates in HD drug development and clinical trial optimization across all stages of HD progression, HDYO brings a unique and important voice to the HD-RSC community,” said Terina Martinez, Ph.D., Executive Director of HD-RSC. “We are excited to add HDYO’s perspective and collaborative energy to our many ongoing efforts in HD-RSC.” More information about the HD-RSC consortium, including mission, leadership, and membership, can be found here.
About Critical Path Institute
Founded in 2005, as a public-private partnership in response to the FDA’s Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
Critical Path Institute is supported by the Food and Drug Administration (FDA) of the Department of Health and Human Services (HHS) and is 56% funded by the FDA/HHS, totaling $23,740,424, and 44% funded by non-government source(s), totaling $18,881,611. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, FDA/HHS or the U.S. Government.
Media Contacts:
Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org
Kissy Black
C-Path
615.310.1894
kblack@c-path.org
